A Protac®-based screening test for activated protein C-resistant factor Va and other defects of the protein C anticoagulant pathway

Blood Coagulation and Fibrinolysis

Volumn 8, Issue 6, 1997, Pages 327-335

  Gable, P S ^a   Le, D T ^b,d   McGehee, W ^c   Rapaport, S I ^b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

APC resistance; Factor V Leiden; Protac ; Protein C; Protein S; Screening test

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5A; BUFFER; CALCIUM; HEPARIN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOPLASTIN; WARFARIN; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; FIBRINOLYTIC AGENT; PEPTIDE; SNAKE VENOM PROTEIN C ACTIVATOR;

ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; GENETIC RISK; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PROTHROMBIN TIME; SCREENING TEST; VEIN THROMBOSIS; BLOOD; BLOOD CLOTTING; DRUG RESISTANCE; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY;

ANTICOAGULANTS; BLOOD COAGULATION; CALCIUM; DRUG RESISTANCE; FACTOR VA; FIBRINOLYTIC AGENTS; HUMANS; INDICATORS AND REAGENTS; PEPTIDES; PROTEIN C; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; THROMBOPLASTIN;

EID: 0030611671     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199709000-00002     Document Type: Article

References (25)

1. Lane DA, Mannucci PM, Bauer KA, et al. Inherited Thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-662.
2. Gable PS, Le DT, Rapaport SI. A Protac®-based screening test for activated protein C-resistant factor Va. J Invest Med 1995; 43 (suppl. 2): 233a (abstract).
3. Stocker K, Fischer H, Meier J, Brogli M, Svendsen L. Protein C activators in snake venoms. Behring Inst Mitt 1986; 79: 37-47.
4. Kraus M, Noah M, Fickenscher K. The PCAT - a simple screening assay for assessing the functionality of the protein C anticoagulant pathway. Thromb Res 1995; 79: 217-222.
5. Robert A, Eschwege V, Hameg H, Drouet L, Aillaud MF. Anticoagulant response to Agkistrodon Contortrix venom (ACV Test): a new global test to screen for defects in the anticoagulant protein C pathway. Thromb Haemost 1996; 75: 562-566.
6. Denson KW, Haddon ME, Reed SV, Davidson S, Littlewood TJ. A more discriminating test for APC resistance and a possible screening test to include protein C and protein S. Thromb Res 1996; 81: 151-156.
7. Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport SI. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 1995; 85: 1704-1711.
8. Le DT, Donnelly K, Wu N, Sevilla B, Rapaport SI. Reliability of a modified tissue factor-dependent factor V assay for activated protein C resistant factor Va using a calcium-containing thromboplastin. Thromb Haemost 1997; 77: 481-485.
9. Liebman HA, Sutherland D, Bacon R, McGehee W. Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance. Br J Haematol 1996; 95: 550-553.
10. Warn-Cramer BJ, Rapaport SI. Evidence suggestive of activation of the intrinsic pathway of blood coagulation after injection of factor Xa/phospholipid into rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 133-139.
11. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52.
12. Seligsohn U, Østerud B, Griffin JH, Rapaport SI. Evidence for the participation of both activated factor XII and activated factor IX in cold-promoted activation of factor VII. Thromb Res 1978; 13: 1049-1056.
13. Gable PS, Le DT, Rapaport SI. The purified protein C activator from the venom of Agkistrodon contortrix contortrix can activate factor V and factor VIII. Thromb Res 1997; 86: 79-84.
14. Preda L, Simioni P, Legnani C, et al. A new global test for the evaluation of the protein C-protein S system. Blood Coag Fibrinol 1996; 7: 465-469.
15. Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-819.
16. Nesheim ME, Canfield WM, Kisiel W, Mann KG. Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J Biol Chem 1982; 257: 1443-1447.
17. Rosing J, Hoekema L, Nicolaes GA, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 27852-27858.
18. Chan-Lam D, Prentice AG, Copplestone JA, Weston M, Williams M, Hutton CW. Avascular necrosis of bone following intensified steroid therapy for acute lymphoblastic leukaemia and high-grade malignant lymphoma. Br J Haematol 1994; 86: 227-230.
19. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-407.
20. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
21. 506-Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
22. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035.
23. Bertina R, Reitsma P, Rosendaal F, Vandenbroucke J. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-453.
24. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538.
25. Zoller B, He X, Dahlback B. Homozygous APC-resistance combined with inherited type 1 protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 1995; 73: 743-745.